You are here

FDA Approves New Oral Contraceptive

Levonorgestrel/ethinyl estradiol tablets 97% effective in phase III trial (Mar. 29)

The FDA has approved Quartette tablets (levonorgestrel/ethinyl estradiol and ethinyl estradiol, Teva Pharmaceuticals) for the prevention of pregnancy. The product was designed to minimize breakthrough bleeding (BTB) between scheduled periods.

The agency’s approval was based on a development program that included results from phase I, II, and III clinical trials designed to evaluate the safety and efficacy of Quartette. The phase III clinical study, which involved more than 3,000 women, found that the product was 97% effective at preventing pregnancy. The most common adverse reactions in this study were headaches, heavy/irregular vaginal bleeding, nausea/vomiting, acne, dysmenorrhea, increased weight, mood changes, anxiety/panic attack, breast pain, and migraines.

The primary clinical trial that evaluated the efficacy of Quartette also assessed BTB. BTB and unscheduled spotting decreased over successive 91-day cycles.

Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) features a 91-day oral regimen, whereby the dose of estrogen increases at three distinct points over the first 84 days and the amount of progestin remains consistent; this is followed by 7 days of 10 mcg of ethinyl estradiol.

Source: Teva Pharmaceuticals; March 29, 2013.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes
In Most Cases, Plaque/Tangle Dissolution Occurred Almost Instantly